Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Adaptive Responses to Monotherapy in Head and Neck Cancer: Interventions for Rationale-Based Therapeutic Combinations.

Jagadeeshan S, Prasad M, Ortiz-Cuaran S, Gregoire V, Saintigny P, Elkabets M.

Trends Cancer. 2019 Jun;5(6):365-390. doi: 10.1016/j.trecan.2019.04.004. Epub 2019 May 28. Review.

PMID:
31208698
2.

Inhibition of the NKp44-PCNA Immune Checkpoint Using a mAb to PCNA.

Kundu K, Ghosh S, Sarkar R, Edri A, Brusilovsky M, Gershoni-Yahalom O, Yossef R, Shemesh A, Soria JC, Lazar V, Joshua BZ, Campbell KS, Elkabets M, Porgador A.

Cancer Immunol Res. 2019 Jul;7(7):1120-1134. doi: 10.1158/2326-6066.CIR-19-0023. Epub 2019 Jun 4.

PMID:
31164357
3.

c-Met as a new marker of cellular senescence.

Boichuck M, Zorea J, Elkabets M, Wolfson M, Fraifeld VE.

Aging (Albany NY). 2019 May 13;11(9):2889-2897. doi: 10.18632/aging.101961.

4.

The long noncoding RNA TP73-AS1 promotes tumorigenicity of medulloblastoma cells.

Varon M, Levy T, Mazor G, Ben David H, Marciano R, Krelin Y, Prasad M, Elkabets M, Pauck D, Ahmadov U, Picard D, Qin N, Borkhardt A, Reifenberger G, Leprivier G, Remke M, Rotblat B.

Int J Cancer. 2019 May 13. doi: 10.1002/ijc.32400. [Epub ahead of print]

PMID:
31081944
5.

Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy.

Badarni M, Prasad M, Balaban N, Zorea J, Yegodayev KM, Joshua BZ, Dinur AB, Grénman R, Rotblat B, Cohen L, Elkabets M.

JCI Insight. 2019 Mar 12;5. pii: 125341. doi: 10.1172/jci.insight.125341.

6.

Tumor Tissue Explant Culture of Patient-Derived Xenograft as Potential Prioritization Tool for Targeted Therapy.

Ghosh S, Prasad M, Kundu K, Cohen L, Yegodayev KM, Zorea J, Joshua BZ, Lasry B, Dimitstein O, Bahat-Dinur A, Mizrachi A, Lazar V, Elkabets M, Porgador A.

Front Oncol. 2019 Jan 22;9:17. doi: 10.3389/fonc.2019.00017. eCollection 2019.

7.

High-Throughput Screening Identified Compounds Sensitizing Tumor Cells to Glucose Starvation in Culture and VEGF Inhibitors In Vivo.

Marciano R, Prasad M, Ievy T, Tzadok S, Leprivier G, Elkabets M, Rotblat B.

Cancers (Basel). 2019 Jan 30;11(2). pii: E156. doi: 10.3390/cancers11020156.

8.

MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer.

Novoplansky O, Fury M, Prasad M, Yegodayev K, Zorea J, Cohen L, Pelossof R, Cohen L, Katabi N, Cecchi F, Joshua BZ, Popovtzer A, Baselga J, Scaltriti M, Elkabets M.

Int J Cancer. 2019 Aug 1;145(3):748-762. doi: 10.1002/ijc.32170. Epub 2019 Feb 11.

PMID:
30694565
9.

Genomic Landscape of Pancreatic Adenocarcinoma in Younger versus Older Patients: Does Age Matter?

Ben-Aharon I, Elkabets M, Pelossof R, Yu KH, Iacubuzio-Donahue CA, Leach SD, Lowery MA, Goodman KA, O'Reilly EM.

Clin Cancer Res. 2019 Apr 1;25(7):2185-2193. doi: 10.1158/1078-0432.CCR-18-3042. Epub 2019 Jan 7.

PMID:
30617137
10.

IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer.

Zorea J, Prasad M, Cohen L, Li N, Schefzik R, Ghosh S, Rotblat B, Brors B, Elkabets M.

Cell Death Dis. 2018 Sep 20;9(10):944. doi: 10.1038/s41419-018-1025-8.

11.

Methods to Study the Role of Progranulin in the Tumor Microenvironment.

Elkabets M, Brook S.

Methods Mol Biol. 2018;1806:155-176. doi: 10.1007/978-1-4939-8559-3_12.

PMID:
29956276
12.

Enhanced ZnR/GPR39 Activity in Breast Cancer, an Alternative Trigger of Signaling Leading to Cell Growth.

Ventura-Bixenshpaner H, Asraf H, Chakraborty M, Elkabets M, Sekler I, Taylor KM, Hershfinkel M.

Sci Rep. 2018 May 25;8(1):8119. doi: 10.1038/s41598-018-26459-5.

13.

PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D.

Toska E, Osmanbeyoglu HU, Castel P, Chan C, Hendrickson RC, Elkabets M, Dickler MN, Scaltriti M, Leslie CS, Armstrong SA, Baselga J.

Science. 2017 Mar 24;355(6331):1324-1330. doi: 10.1126/science.aah6893. Erratum in: Science. 2019 Jan 25;363(6425):.

14.

P-selectin is a nanotherapeutic delivery target in the tumor microenvironment.

Shamay Y, Elkabets M, Li H, Shah J, Brook S, Wang F, Adler K, Baut E, Scaltriti M, Jena PV, Gardner EE, Poirier JT, Rudin CM, Baselga J, Haimovitz-Friedman A, Heller DA.

Sci Transl Med. 2016 Jun 29;8(345):345ra87. doi: 10.1126/scitranslmed.aaf7374.

15.

Streptococcus pneumoniae fructose-1,6-bisphosphate aldolase, a protein vaccine candidate, elicits Th1/Th2/Th17-type cytokine responses in mice.

Elhaik Goldman S, Dotan S, Talias A, Lilo A, Azriel S, Malka I, Portnoi M, Ohayon A, Kafka D, Ellis R, Elkabets M, Porgador A, Levin D, Azhari R, Swiatlo E, Ling E, Feldman G, Tal M, Dagan R, Mizrachi Nebenzahl Y.

Int J Mol Med. 2016 Apr;37(4):1127-38. doi: 10.3892/ijmm.2016.2512. Epub 2016 Mar 1.

PMID:
26935978
16.

Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy.

Scaltriti M, Elkabets M, Baselga J.

Clin Cancer Res. 2016 Mar 15;22(6):1313-7. doi: 10.1158/1078-0432.CCR-15-1458. Epub 2016 Jan 13. Review.

17.

AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.

Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelossof RA, Brook S, Benzaken AO, Rodon J, Morse N, Yan JJ, Liu M, Das R, Chen Y, Tam A, Wang H, Liang J, Gurski JM, Kerr DA, Rosell R, Teixidó C, Huang A, Ghossein RA, Rosen N, Bivona TG, Scaltriti M, Baselga J.

Cancer Cell. 2015 Apr 13;27(4):533-46. doi: 10.1016/j.ccell.2015.03.010.

18.

Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment.

Castel P, Toska E, Zumsteg ZS, Carmona FJ, Elkabets M, Bosch A, Scaltriti M.

Mol Cell Oncol. 2014 Oct 29;1(3):e963447. doi: 10.4161/23723548.2014.963447. eCollection 2014 Jul-Sep. Review.

19.

Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.

Tao JJ, Castel P, Radosevic-Robin N, Elkabets M, Auricchio N, Aceto N, Weitsman G, Barber P, Vojnovic B, Ellis H, Morse N, Viola-Villegas NT, Bosch A, Juric D, Hazra S, Singh S, Kim P, Bergamaschi A, Maheswaran S, Ng T, Penault-Llorca F, Lewis JS, Carey LA, Perou CM, Baselga J, Scaltriti M.

Sci Signal. 2014 Mar 25;7(318):ra29. doi: 10.1126/scisignal.2005125.

20.

mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.

Elkabets M, Vora S, Juric D, Morse N, Mino-Kenudson M, Muranen T, Tao J, Campos AB, Rodon J, Ibrahim YH, Serra V, Rodrik-Outmezguine V, Hazra S, Singh S, Kim P, Quadt C, Liu M, Huang A, Rosen N, Engelman JA, Scaltriti M, Baselga J.

Sci Transl Med. 2013 Jul 31;5(196):196ra99. doi: 10.1126/scitranslmed.3005747. Erratum in: Sci Transl Med. 2018 Nov 14;10(467):.

21.

Unique Versus Redundant Functions of IL-1α and IL-1β in the Tumor Microenvironment.

Voronov E, Dotan S, Krelin Y, Song X, Elkabets M, Carmi Y, Rider P, Idan Cohen, Romzova M, Kaplanov I, Apte RN.

Front Immunol. 2013 Jul 8;4:177. doi: 10.3389/fimmu.2013.00177. eCollection 2013.

22.

The natural cytotoxicity receptor 1 contribution to early clearance of Streptococcus pneumoniae and to natural killer-macrophage cross talk.

Elhaik-Goldman S, Kafka D, Yossef R, Hadad U, Elkabets M, Vallon-Eberhard A, Hulihel L, Jung S, Ghadially H, Braiman A, Apte RN, Mandelboim O, Dagan R, Mizrachi-Nebenzahl Y, Porgador A.

PLoS One. 2011;6(8):e23472. doi: 10.1371/journal.pone.0023472. Epub 2011 Aug 22.

23.

Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis.

Carmi Y, Rinott G, Dotan S, Elkabets M, Rider P, Voronov E, Apte RN.

J Immunol. 2011 Mar 15;186(6):3462-71. doi: 10.4049/jimmunol.1002901. Epub 2011 Feb 7.

24.

Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice.

Elkabets M, Gifford AM, Scheel C, Nilsson B, Reinhardt F, Bray MA, Carpenter AE, Jirström K, Magnusson K, Ebert BL, Pontén F, Weinberg RA, McAllister SS.

J Clin Invest. 2011 Feb;121(2):784-99. doi: 10.1172/JCI43757. Epub 2011 Jan 25.

25.

IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function.

Elkabets M, Ribeiro VS, Dinarello CA, Ostrand-Rosenberg S, Di Santo JP, Apte RN, Vosshenrich CA.

Eur J Immunol. 2010 Dec;40(12):3347-57. doi: 10.1002/eji.201041037.

26.

Sialylation of 3-methylcholanthrene-induced fibrosarcoma determines antitumor immune responses during immunoediting.

Cohen M, Elkabets M, Perlmutter M, Porgador A, Voronov E, Apte RN, Lichtenstein RG.

J Immunol. 2010 Nov 15;185(10):5869-78. doi: 10.4049/jimmunol.1001635. Epub 2010 Oct 18.

27.

Targeting of polymeric nanoparticles to lung metastases by surface-attachment of YIGSR peptide from laminin.

Sarfati G, Dvir T, Elkabets M, Apte RN, Cohen S.

Biomaterials. 2011 Jan;32(1):152-61. doi: 10.1016/j.biomaterials.2010.09.014. Epub 2010 Oct 14.

PMID:
20889205
28.

IL-1-induced inflammation promotes development of leishmaniasis in susceptible BALB/c mice.

Voronov E, Dotan S, Gayvoronsky L, White RM, Cohen I, Krelin Y, Benchetrit F, Elkabets M, Huszar M, El-On J, Apte RN.

Int Immunol. 2010 Apr;22(4):245-57. doi: 10.1093/intimm/dxq006. Epub 2010 Feb 24.

PMID:
20181656
29.

Differences in the sialylation patterns of membrane stress proteins in chemical carcinogen-induced tumors developed in BALB/c and IL-1alpha deficient mice.

Avidan A, Perlmutter M, Tal S, Oraki O, Kapp T, Krelin Y, Elkabets M, Dotan S, Apte RN, Lichtenstein RG.

Glycoconj J. 2009 Dec;26(9):1181-95. doi: 10.1007/s10719-009-9238-9.

PMID:
19430902
30.

Host-derived interleukin-1alpha is important in determining the immunogenicity of 3-methylcholantrene tumor cells.

Elkabets M, Krelin Y, Dotan S, Cerwenka A, Porgador A, Lichtenstein RG, White MR, Zoller M, Iwakura Y, Dinarello CA, Voronov E, Apte RN.

J Immunol. 2009 Apr 15;182(8):4874-81. doi: 10.4049/jimmunol.0803916.

31.

Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors.

Krelin Y, Voronov E, Dotan S, Elkabets M, Reich E, Fogel M, Huszar M, Iwakura Y, Segal S, Dinarello CA, Apte RN.

Cancer Res. 2007 Feb 1;67(3):1062-71.

32.

The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions.

Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y, Voronov E.

Cancer Metastasis Rev. 2006 Sep;25(3):387-408. Review.

PMID:
17043764
33.

Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions.

Apte RN, Krelin Y, Song X, Dotan S, Recih E, Elkabets M, Carmi Y, Dvorkin T, White RM, Gayvoronsky L, Segal S, Voronov E.

Eur J Cancer. 2006 Apr;42(6):751-9. Epub 2006 Mar 10. Review.

PMID:
16530403
34.

Differential effects of monastrol in two human cell lines.

Leizerman I, Avunie-Masala R, Elkabets M, Fich A, Gheber L.

Cell Mol Life Sci. 2004 Aug;61(16):2060-70.

PMID:
15316655

Supplemental Content

Loading ...
Support Center